Drug Profile
Propranolol/etodolac - Vicus Therapeutics
Alternative Names: VT 11CR; VT-122Latest Information Update: 03 Sep 2021
Price :
$50
*
At a glance
- Originator Vicus Therapeutics LLC
- Developer Vicus Therapeutics
- Class Indoleacetic acids; Naphthalenes; Nonsteroidal anti-inflammatories; Propanolamines
- Mechanism of Action Beta-adrenergic receptor antagonists; Cyclo-oxygenase 1 inhibitors; Cyclo-oxygenase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cachexia; Liver cancer; Lung cancer; Pancreatic cancer; Prostate cancer; Solid tumours
Most Recent Events
- 03 Sep 2021 Discontinued - Clinical-Phase-Unknown for Pancreatic cancer (Combination therapy, Metastatic disease) in USA (PO)
- 03 Sep 2021 Discontinued - Phase-I for Lung cancer (Combination therapy, Metastatic disease) in USA (PO)
- 03 Sep 2021 Discontinued - Phase-I for Solid tumours (Combination therapy, Metastatic disease) in USA (PO)